In search of a real "targeted" therapy for thyroid cancer.
Where this comes from
- Record sourced from PubMed, PMID 22451620.
- Also identified by DOI 10.1158/1078-0432.CCR-12-0153.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Over the past 5 years, patients with progressive radioactive iodine-refractory thyroid cancer have responded to "targeted" multikinase inhibitors, which inhibit angiogenesis and not the tumor cell. Here, selumetinib targets the mitogen-activated protein kinase pathway in papillary thyroid carcinoma and shows limited single-agent activity in the patients with tumors that harbor the (V600E)BRAF mutation.
Medical subject headings
- Adenocarcinoma, Follicular
- Benzimidazoles
- Pharmacogenetics
- Thyroid Neoplasms